Chronic hepatitis C: decision analytic modeling
Zechmeister I, Wild C
Record ID 32006000692
German
Authors' objectives:
To evaluate the effectiveness and cost-effectiveness of different antiviral treatment strategies (including actual genotype-specific Austrian guidelines) in previously untreated patients with chronic hepatitis C and elevated ALT levels.
Authors' results and conclusions:
Compared to NoAVT, GuidePegIFN+RBV increased life expectancy by 4.2 life years (4.4 QALYs) and IFN+RBV increased life expectancy by 2.5 years (2.6 QALYs). GuidePegIFN+RBV dominated IFN+RBV with a discounted ICER of 9000 euros per QALY gained compared to NoAVT. Sensitivity analyses showed robustness of the results.
Authors' recommendations:
Administering peginterferon and ribavirin according to new Austrian guidelines should increase life expectancy and long-term quality of life and should be cost-effective compared to other well-accepted medical interventions in the Austrian health care system.
Details
Project Status:
Completed
URL for project:
http://eprints.hta.lbg.ac.at/678/
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Decision Making
- Decision Support Techniques
- Models, Statistical
- Hepatitis C, Chronic
Contact
Organisation Name:
Institute of Technology Assessment
Contact Address:
Ludwig Boltzmann Institut fur Health Technology Assessment, Garnisongasse 7/rechte Stiege Mezzanin (Top 20) 1090 Vienna, Austria. Tel: +43 (0)1 236 8119 12; Fax: +43 (0)1 236 8119 99
Contact Name:
beate.guba@hta.igb.ac.at
Contact Email:
beate.guba@hta.igb.ac.at
Copyright:
HTA Unit of the Institute of Technology Assessment, ITA of the Austrian Academy of Science (ITA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.